SPHK2

Across TCGA pan-cancer cohorts, SPHK2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPHK2 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SPHK2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SPHK2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

GBM, PDAC, and LUAD are the cancer types where SPHK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.246	0.549	.013	9	view →
PDAC	OS	Tertile	III,IV	0.869	0.144	.024	4	view →
LUAD	DFS	Quartile	II,III,IV	0.635	1.000	.040	4	view →
LSCC	OS	Median	All	0.800	1.000	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPHK2–GBM (OS)

Open the GBM breakdown →